VONOPRAZAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H16FN3O2S
Molecular Weight	345.391
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CC=CN=C3

InChI

InChIKey=BFDBKMOZYNOTPK-UHFFFAOYSA-N

InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3

HIDE SMILES / InChI

Description
Sources: https://www.takeda.com/news/2015/20150226_6922.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25744862| https://www.ncbi.nlm.nih.gov/pubmed/20624992

Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20624992	Blocker 537		0.003 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Gastric ulcer 67 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Curative	Approved 8429	TAKECAB Approved Use Unknown
Duodenal ulcer 42 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Curative	Approved 8429	TAKECAB Approved Use Unknown
Reflux esophagitis 3 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Curative	Approved 8429	TAKECAB Approved Use Unknown
Helicobacter pylori gastritis 3 Sources: https://www.takeda.com/news/2015/20150226_6922.html	Primary	Approved 8429	TAKECAB Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatment and secondary prevention of reflux esophagitis, respectively, at 10 mg once daily for the secondary prevention of low-dose aspirin- or non-steroidal anti-inflammatory drug-induced peptic ulcer, and at 20 mg twice daily in combination with clarithromycin and amoxicillin for the eradication of Helicobacter pylori.

Route of Administration: Oral

In Vitro Use Guide

TAK-438 (Vonoprazan) inhibited H(+),K(+)-ATPase activity in porcine gastric microsomes with IC(50) values of 0.019 μM at pH 6.5. The inhibitory activity of TAK-438 was unaffected by ambient pH. The inhibition by TAK-438 was reversible and achieved in a K(+)-competitive manner.

Name

Type

Language

VONOPRAZAN

Official Name

English

vonoprazan [INN]

Common Name

English

1H-PYRROLE-3-METHANAMINE, 5-(2-FLUOROPHENYL)-N-METHYL-1-(3-PYRIDINYLSULFONYL)-

Systematic Name

English

1-(5-(2-FLUOROPHENYL)-1-(PYRIDINE-3-SULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE

Systematic Name

English

VONOPRAZAN [USAN]

Common Name

English

VONOPRAZAN [MI]

Common Name

English

Vonoprazan [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29701